Approved CD20×CD3 bispecifics (epcoritamab, glofitamab, mosunetuzumab) deliver meaningful ORR/CR in heavily pretreated DLBCL, but PFS remains modest, motivating combination strategies.

Phase 1 study with ADG138 for patients with advanced solid tumors is expected to begin in China in the fourth quarter of 2026ADG138 is a ...

Following hematopoietic SCT (HSCT) for non-malignant disorders (NMDs) variable donor chimerism among lympho-hematopoietic lines may be observed. We retrospectively evaluated early post-HSCT, ...

Targeting the T-cell co-receptor cluster of differentiation 3 (CD3) in type 1 diabetes (T1D) mellitus may impede the autoimmune attack initiated by a triggering event, thus slowing or preventing ...

BOSTON, April 01, 2026 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana”), a biotechnology company developing its lead candidate, intranasal foralumab, a fully human, anti-CD3 ...

Adagene Inc. announced that China's National Medical Products Administration (NMPA) has approved the company's investigational new drug (IND) application for ADG138, a double-masked HER2 CD3 ...